Literature DB >> 270389

A phase 1 and 2 trial of rubidazone in patients with acute leukemia.

R S Benjamin, M J Keating, K B McCredie, G P Bodey, E J Freireich.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 270389

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  Treatment of patients with refractory myelogenous leukemia with BCOMM[1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)].

Authors:  T S Herman; B G Durie; J J Hutter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Distribution and metabolism of rubidazone and daunorubicin in mice.

Authors:  R Baurain; D Deprez-De Campeneere; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Biological activities of rubidazone.

Authors:  R Maral
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.